Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan.
Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan; Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Transl Res. 2020 Jul;221:44-57. doi: 10.1016/j.trsl.2020.03.001. Epub 2020 Mar 10.
The age-associated decline in muscle mass has become synonymous with physical frailty among the elderly due to its major contribution in reduced muscle function. Alterations in protein and redox homeostasis along with chronic inflammation, denervation, and hormonal dysregulation are all hallmarks of muscle wasting and lead to clinical sarcopenia in older adults. Reduction in skeletal muscle mass has been observed and reported in the scientific literature for nearly 2 centuries; however, identification and careful examination of molecular mediators of age-related muscle atrophy have only been possible for roughly 3 decades. Here we review molecular targets of recent interest in age-related muscle atrophy and briefly discuss emerging small molecule therapeutic treatments for muscle wasting in sarcopenic susceptible populations.
随着肌肉功能的下降，肌肉质量随年龄的衰减与老年人的身体虚弱已成为同义词。蛋白质和氧化还原平衡的改变，以及慢性炎症、去神经支配和激素失调，都是肌肉消耗的标志，并导致老年人的临床肌肉减少症。在近 200 年的科学文献中都观察到并报道了骨骼肌质量的减少；然而，只有大约 30 年的时间才能确定和仔细研究与年龄相关的肌肉萎缩的分子介质。在这里，我们回顾了最近与年龄相关的肌肉萎缩的分子靶点，并简要讨论了针对易发生肌肉减少症的人群的肌肉消耗的新兴小分子治疗方法。
